87 related articles for article (PubMed ID: 10534323)
1. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs.
Huskey SE; Luffer-Atlas D; Dean BJ; McGowan EM; Feeney WP; Chiu SH
Drug Metab Dispos; 1999 Nov; 27(11):1367-73. PubMed ID: 10534323
[TBL] [Abstract][Full Text] [Related]
2. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs.
Benchaoui HA; Cox SR; Schneider RP; Boucher JF; Clemence RG
J Vet Pharmacol Ther; 2007 Aug; 30(4):336-44. PubMed ID: 17610407
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
[TBL] [Abstract][Full Text] [Related]
5. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
Majumdar AK; Howard L; Goldberg MR; Hickey L; Constanzer M; Rothenberg PL; Crumley TM; Panebianco D; Bradstreet TE; Bergman AJ; Waldman SA; Greenberg HE; Butler K; Knops A; De Lepeleire I; Michiels N; Petty KJ
J Clin Pharmacol; 2006 Mar; 46(3):291-300. PubMed ID: 16490805
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine.
Pao LH; Hsiong CH; Hu OY; Wang JJ; Ho ST
Drug Metab Dispos; 2005 Mar; 33(3):395-402. PubMed ID: 15608131
[TBL] [Abstract][Full Text] [Related]
9. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
Yang JZ; Chen W; Borchardt RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):840-8. PubMed ID: 12388671
[TBL] [Abstract][Full Text] [Related]
10. Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation.
Lin JH; Chen IW; Chiba M; Nishime JA; Deluna FA
Drug Metab Dispos; 2000 Apr; 28(4):460-6. PubMed ID: 10725315
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir.
Choi WS; Im GJ; Kim DK; Kim TK; Jung I; Kim TS; Lee SJ; Lee N; Kim YW; Kim JS; Chang K
Drug Metab Dispos; 2001 Jul; 29(7):945-9. PubMed ID: 11408358
[TBL] [Abstract][Full Text] [Related]
12. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs.
Plum A; Agerso H; Andersen L
Drug Metab Dispos; 2000 Feb; 28(2):155-60. PubMed ID: 10640512
[TBL] [Abstract][Full Text] [Related]
15. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.
Singh R; Chen IW; Jin L; Silva MV; Arison BH; Lin JH; Wong BK
Drug Metab Dispos; 2001 Dec; 29(12):1578-87. PubMed ID: 11717177
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist.
Fujitaki JM; Cable EE; Ito BR; Zhang BH; Hou J; Yang C; Bullough DA; Ferrero JL; van Poelje PD; Linemeyer DL; Erion MD
Drug Metab Dispos; 2008 Nov; 36(11):2393-403. PubMed ID: 18703645
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs.
Lin JH; Chen IW; King J
J Pharmacol Exp Ther; 1992 Oct; 263(1):105-11. PubMed ID: 1403775
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the involvement of a pulmonary first-pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration.
Imai T; Yoshigae Y; Hosokawa M; Chiba K; Otagiri M
J Pharmacol Exp Ther; 2003 Dec; 307(3):1234-42. PubMed ID: 14534358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
